治療歴のある進行肝細胞がんに対するcabozantinib、プラセボと比較してOSおよびPFSを延長【NEJM】

N Engl J Med 2018; 379: 54-6

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

BACKGROUND
Cabozantinib inhibits tyrosine kinases, including vascular endothelial growth factor receptors 1, 2, and 3, MET, and AXL, which are implicated in the progression of hepatocellular carcinoma and the development of resistance to sorafenib, the standard initial treatment for advanced disease. This randomized, double-blind, phase 3 trial evaluated cabozantinib as compared with placebo in previously treated patients with advanced hepatocellular carcinoma.

 

 

 

コメント

Leave a comment

Your email address will not be published.


*